ReviewFrontiers in endocrinology2022
Sirtuin 1 in Chronic Kidney Disease and Therapeutic Potential of Targeting Sirtuin 1.
Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Sirtuin 1 deficiency mediates chronic kidney disease-induced inflammaging cardiovascular calcification.Molecular biomedicine · 2026Article
- Uremic toxin p‑cresyl sulfate enhances the calcification of aortic valvular interstitial cells via klotho/sirtuin‑1 signaling.Molecular medicine reports · 2026Article
- Salvia miltiorrhiza (Danshen) and its extracts in the alternative treatment of diabetic nephropathy: mechanisms and clinical perspectives.Journal of natural medicines · 2026Review
- Discovery of 5-(Substituted Phenyl)-2-aryl Benzimidazole Derivatives as SIRT1 Activators: Their Design,Current medicinal chemistry · 2026Article
- Phosphate and Inflammation in Health and Kidney Disease.International journal of molecular sciences · 2025Review
- Elevated Sirtuin 1 Levels in Patients with Chronic Kidney Disease, Including on Peritoneal Dialysis: Associations with Cardiovascular Risk and Peritoneal Fibrosis.International journal of molecular sciences · 2025Article
- Microbiota-derived corisin accelerates kidney fibrosis by promoting cellular aging.Nature communications · 2025Article
- Aptamer-targeted anti-miR RNA construct based on 3WJ as a new approach for the treatment of chronic kidney disease in an experimental model.Gene therapy · 2025Article
- Selenium, a Notable Micronutrient: A Crucial Element in the Context of All-Cause Long-Term Mortality in Renal Failure.Biological trace element research · 2025Article
- Pathophysiology of vascular ageing and the effect of novel cardio-renal protective medications in preventing progression of chronic kidney disease in people living with diabetes.Diabetic medicine : a journal of the British Diabetic Association · 2025Review
- Liu Wei Di Huang Decoction Alleviates Renal Fibrosis by Inhibiting Endothelial Mesenchymal Transitions via Upregulating Sirt1 Expression and Inhibiting the Wnt/β-Catenin Signaling Pathway.Drug design, development and therapy · 2025Article
- Homotherapy for heteropathy of chronic kidney disease and oligoasthenozoospermia through regulating SIRT1/NF-κB pathway by Shenqi pills.Frontiers in pharmacology · 2025Article
- Understanding Vascular Calcification in Chronic Kidney Disease: Pathogenesis and Therapeutic Implications.International journal of molecular sciences · 2024Review
- Elucidation of anti-human melanoma and anti-aging mechanisms of compounds from green seaweed Caulerpa racemosa.Scientific reports · 2024Article
- Renal Fibrosis: SIRT1 Still of Value.Biomedicines · 2024Review
- Potential Nephroprotective Effect of Kaempferol: Biosynthesis, Mechanisms of Action, and Clinical Prospects.Advances in pharmacological and pharmaceutical sciences · 2024Review
- Efficacy of Oroxylin A in ameliorating renal fibrosis with emphasis on Sirt1 activation and TGF-β/Smad3 pathway modulation.Frontiers in pharmacology · 2024Article
- Oxidative stress and senescence in aging kidneys: the protective role of SIRT1.EXCLI journal · 2024Review
- Early aging and premature vascular aging in chronic kidney disease.Clinical kidney journal · 2023Review
- Sweroside plays a role in mitigating high glucose-induced damage in human renal tubular epithelial HK-2 cells by regulating the SIRT1/NF-κB signaling pathway.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence and prevalence of chronic kidney disease (CKD) continue to increase worldwide remaining as a major public health burden. CKD eventually progresses to end-stage kidney failure and patients with CKD have high morbidity and mortality. Sirtuin 1 (SIRT1), a NAD+-dependent deacetylases, has significant renal protective effects through its regulation of fibrosis, apoptosis, and senescence, oxidative stress, inflammation and aging process. The renal protective effects of Sirt1 have been described in many kidney diseases such as diabetic kidney disease and HIV-related kidney disease. SIRT1 also has protective effects against vascular calcification and therefore could be developed as a therapy for both CKD and CKD complications. In this narrative review, we will give an overview of the recent progress on the role of SIRT1 and its downstream pathways in CKD. We will also discuss potential therapeutic approach by activating SIRT1-related pathway in patients with CKD. The purpose is to hope to provide some insights on the future direction of the research in the field of SIRT1 for CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.